C.K. Cornelia Ding
Dr. C.K. Cornelia Ding's innovative methodologies enhance understanding of genitourinary cancers through the integration of pathology with cutting-edge technologies. As an Assistant Professor specializing in Surgical Pathology at the University of California-San Francisco, she brings a wealth of expertise in neoplastic diseases affecting the prostate, urinary bladder, kidney, and testis. Her work is pivotal in advancing the diagnosis and management of these conditions, leveraging her deep knowledge of functional genomics, spatial transcriptomics, and the application of artificial intelligence in digital pathology. Dr. Ding's research portfolio is both diverse and impactful, with significant contributions to the understanding of NADPH phosphatase regulation and its implications in cancer biology. Her studies on prostate cancer in transgender individuals highlight her commitment to addressing complex and under-researched areas in pathology, ensuring that her work is both inclusive and comprehensive. Additionally, she has explored the challenges and pitfalls in interpreting immunohistochemistry, providing valuable insights that enhance diagnostic accuracy. Her academic journey is marked by prestigious recognitions, including the Jonathan I. Epstein Fellowship at Johns Hopkins University, which underscores her exceptional contributions to the field of pathology. Dr. Ding's commitment to fostering diversity and inclusion in research is further evidenced by her receipt of a Diversity, Equity, and Inclusion Research Award, reflecting her dedication to creating a more equitable scientific community. At UCSF, Dr. Ding is not only a researcher but also an educator, inspiring the next generation of pathologists with her passion and expertise. Her work continues to push the boundaries of what is possible in the realm of genitourinary cancer research, making significant strides towards more personalized and effective treatment strategies. Through her innovative research and dedication to teaching, Dr. Ding is shaping the future of pathology, ensuring that advancements in technology and genomics are seamlessly integrated into clinical practice. Her contributions are paving the way for more precise and individualized approaches to cancer diagnosis and treatment, ultimately improving patient outcomes.